Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DNTHBullishIndustry Newsnews

High materiality8/10

DNTH Advances Claseprubart at AANEM With CIDP and MG Milestones

Sep 29, 2026, 10:21 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive trial signals (75% CIDP responders) and orphan designation, plus multiple near-term readouts, create multiple re-rating catalysts within 12-18 months, despite ongoing development risk typical of early-stage biotech.

AI summary

What happened, with direct paths to the underlying reporting

Dianthus Therapeutics announced five Claseprubart presentations at AANEM, including an oral CAPTIVATE interim for CIDP and four MG-focused posters. A 75% CIDP responder rate and favorable Phase 2 MaGic safety data underpin ongoing Phase 3 development, with key catalysts in Dec 2026 and YE 2026 for CAPTIVATE Part B, followed by EMERGE top-line readouts in 2H 2028.

DNTH to present 1 oral and 4 posters on Claseprubart at AANEM.
CAPTIVATE CIDP interim shows 75% responses in Part A. Supports ongoing Phase 3.
Orphan Drug Designation for MG granted May 2026.
Phase 2 MaGic open-label extension shows sustained efficacy and safety.
MoMeNtum top-line data due Dec 2026; CAPTIVATE Part B YE26; EMERGE 2H28.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.